Literature DB >> 7600115

Hormonal regulation of serum lipoprotein(a) levels. Contrasting effects of growth hormone and insulin-like growth factor-I.

H Olivecrona1, A G Johansson, E Lindh, S Ljunghall, L Berglund, B Angelin.   

Abstract

In response to treatment with growth hormone, serum levels of lipoprotein(a) increase, while those of LDL cholesterol decrease. To establish if increased levels of insulin-like growth factor-I may be of importance for these changes, we analyzed serum lipoprotein concentrations in 11 male patients with idiopathic osteoporosis who were treated with growth hormone (2 IU.m-2.d-1) or insulin-like growth factor-I (80 micrograms.kg-1.d-1) in a randomized, double-blind, cross-over study. LDL cholesterol was reduced by 0.7 mmol/L (P < .01) during growth hormone treatment but was not affected when the same patients received insulin-like growth factor-I. In contrast, mean lipoprotein(a) levels increased from 519 to 571 mg/L (P < .03) in response to growth hormone but were reduced from 538 to 478 mg/L (P < .04) during treatment with insulin-like growth factor-I. These results indicate that growth hormone exerts its effects on lipoprotein metabolism independent of insulin-like growth factor-I. Furthermore, the results suggest that treatment with insulin-like growth factor-I may reduce lipoprotein(a) levels.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7600115     DOI: 10.1161/01.atv.15.7.847

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  7 in total

1.  Relationship of lipoprotein(a) levels to physical activity and family history of coronary heart disease.

Authors:  S Martín; R Elosua; M I Covas; M Pavesi; J Vila; J Marrugat
Journal:  Am J Public Health       Date:  1999-03       Impact factor: 9.308

2.  Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population.

Authors:  Lin Ding; An Song; Meng Dai; Min Xu; Wanwan Sun; Baihui Xu; Jichao Sun; Tiange Wang; Yu Xu; Jieli Lu; Weiqing Wang; Yufang Bi; Guang Ning
Journal:  J Lipid Res       Date:  2015-02-03       Impact factor: 5.922

3.  Plasma cholesteryl ester transfer protein and lipoprotein levels during treatment of growth hormone-deficient adult humans.

Authors:  A J Carrilho; M B Cunha-Neto; V S Nunes; A M Lottenberg; W L Medina; E R Nakandakare; N R Musolino; M D Bronstein; E C Quintão
Journal:  Lipids       Date:  2001-06       Impact factor: 1.880

4.  Lipoprotein(a) and risk of type 2 diabetes.

Authors:  Samia Mora; Pia R Kamstrup; Nader Rifai; Børge G Nordestgaard; Julie E Buring; Paul M Ridker
Journal:  Clin Chem       Date:  2010-05-28       Impact factor: 8.327

5.  Regulation of rat hepatic low density lipoprotein receptors. In vivo stimulation by growth hormone is not mediated by insulin-like growth factor I.

Authors:  M Rudling; H Olivecrona; G Eggertsen; B Angelin
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

Review 6.  Metabolic effects of recombinant human insulin-like growth factor-I in humans: comparison with recombinant human growth hormone.

Authors:  N Mauras; M W Haymond
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

7.  Fasting levels of growth hormone are associated with carotid intima media thickness but are not affected by fluvastatin treatment.

Authors:  Erik Hallengren; Peter Almgren; Maria Rosvall; Gerd Östling; Margaretha Persson; Andreas Bergmann; Joachim Struck; Gunnar Engström; Bo Hedblad; Olle Melander
Journal:  BMC Cardiovasc Disord       Date:  2017-05-16       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.